Lori Hu

Lori Hu has a long and varied work experience. From 2012 to 2015, they were the Associate Director of Business Development at Bristol-Myers Squibb. From 2014 to 2015, they were a VC Associate at S.R. One Ltd. During that same period, they were also a Board Observer at Moximed and Ivantis, Inc. From 2015 to 2021, they were the Managing Director at Vertex Ventures HC. From 2018 to 2019, they were a Board Director at Palleon Pharmaceuticals, BlackThorn Therapeutics, and Elevation Oncology. Finally, from 2021 to 2022, they were a Board Director at Neuspera Medical Inc. and Indapta Therapeutics.

Lori Hu received their Master of Business Administration (M.B.A.) from The Wharton School, their Master's Degree in International Studies from The Lauder Institute - University of Pennsylvania, and their Bachelor of Science in Biomedical Engineering from Duke University.